ArticleCancer letters2018

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.

Chun-Te Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.